EIKONOKLASTES THERAPEUTICS, INC.
About EIKONOKLASTES THERAPEUTICS, INC.
Eikonoklastes Therapeutics, Inc. is an early-stage biopharmaceutical company focused on rapidly advancing innovative medicines for areas of significant unmet clinical need, starting with neurodegenerative diseases such as ALS. The company develops first-in-class gene therapy platforms that provide extra copies of critical genes to cause overexpression of neurotrophic factors essential for neuromuscular signaling and function. It is headquartered at 2356 Park Avenue, Unit 17, Cincinnati, Ohio, 45206, United States and maintains the website eikonoklastes.com.
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Raised $16.06M via private placement in a filing dated around September 2025.
- Total funding reported at $25.48M including a Series B round per CB Insights.
- Developing first-in-class gene supplement therapy for ALS and other neuromuscular diseases.
- Headquartered in Cincinnati with a focus on accelerated clinical development strategies.
- Pipeline targets high unmet needs in neurodegenerative diseases and certain cancers.
Ask StreetZero about EIKONOKLASTES THERAPEUTICS, INC.
Put our AI to work on this deal.
Similar companies
Other Pharmaceuticals deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account